across solid tumors with high microsatellite instability status as well as for Keytruda combined with Eisai and Merck’s ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Investors will be looking out for updates on Winrevair’s commercial uptake, and comments on Keytruda will also be in focus. UBS says, “On 3Q24 results, we are broadly in line with consensus ...

Credit: SewCreamStudio / Shutterstock. Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with ...

Analysts forecast 'Sales- Oncology- Keytruda' to reach $7.38 billion ... analysts suggests that 'Sales- Oncology- Alliance revenue- Lenvima' will likely reach $275.08 million.

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...